RemeGen Co., Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGMF research report →
Companywww.remegen.com
RemeGen Co. , Ltd. , a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
- CEO
- Jianmin Fang
- IPO
- 2021
- Employees
- 2,999
- HQ
- Yantai, CN
Price Chart
Valuation
- Market Cap
- $6.79B
- P/E
- 52.63
- P/S
- 19.87
- P/B
- 17.29
- EV/EBITDA
- 62.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.14%
- Op Margin
- 27.96%
- Net Margin
- 38.17%
- ROE
- 42.27%
- ROIC
- 15.45%
Growth & Income
- Revenue
- $3.17B · 85.20%
- Net Income
- $690.24M · 147.01%
- EPS
- $1.26 · 146.15%
- Op Income
- $126.84M
- FCF YoY
- 90.28%
Performance & Tape
- 52W High
- $12.85
- 52W Low
- $5.06
- 50D MA
- $11.08
- 200D MA
- $9.45
- Beta
- 0.48
- Avg Volume
- 101
Get TickerSpark's AI analysis on REGMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our REGMF Coverage
We haven't published any research on REGMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate REGMF Report →